Last reviewed · How we verify
NCT06278038
Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Venlafaxine Hydrochloride Sustained-release Tablets in Patients With Major Depression Disorder
NA trial testing Toludesvenlafaxine hydrochloride sustained-release tablets in Major Depression Disorder in 84 participants. Completed in 19 November 2024.
10 November 2024
Quick facts
| Lead sponsor | First Affiliated Hospital of Zhejiang University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 84 |
| Start date | 22 February 2024 |
| Primary completion | 10 November 2024 |
| Estimated completion | 19 November 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Toludesvenlafaxine hydrochloride sustained-release tablets — full drug profile →
- Venlafaxine hydrochloride sustained-release tablets — full drug profile →
Conditions studied
- Major Depression Disorder — all drugs for Major Depression Disorder →
Sponsor
First Affiliated Hospital of Zhejiang University
Who can join
Adults 18 to 65, any sex, with Major Depression Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in the treatment of major depression disorder compared to venlafaxine hydrochloride sustained-release tablets, to provide evidence-based basis for clinical rational drug use.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06278038
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Toludesvenlafaxine hydrochloride sustained-release tablets
Trials testing the same drug.
- NCT06270433 — Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets Versus Desvenlafaxine Succinate Sustai · NA · recruiting
- NCT06026917 — Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Ext · Phase 4 · unknown
Other recruiting trials for Major Depression Disorder
Currently open trials in the same condition.
- NCT07039370 — Molecular Signatures of TMS Response in Treatment-Resistant Depression · NA · recruiting
- NCT06671977 — Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans · Phase 1 · recruiting
- NCT07111169 — Neuromodulation and Attention Deficits in MDD · NA · recruiting
Other First Affiliated Hospital of Zhejiang University trials
Trials by the same sponsor.
- NCT07537192 — Inulin-Spirulina Co-intervention for Insomnia Disorder · NA · not yet recruiting
- NCT07510867 — 18F-FAPI PET/CT and MRI in Gastric Cancer · not yet recruiting
- NCT07589647 — Research on the Efficacy and Safety of Targeted Suprachiasmatic Nucleus Electrical Stimulation for Improving Metabolic D · NA · recruiting
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07468162 — Characteristic Electroencephalogram of General Anesthesia · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06278038 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital of Zhejiang University
- Last refreshed: 1 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06278038.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing